GoldenGolden
Advanced Search
Magenta Therapeutics

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases.

Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases that is headquartered in Cambridge, Massachusetts and was founded in 2016 by Jason Gardner.

Funding
Series A

On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.

Series B

On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.

Series C

On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.

Timeline

April 9, 2018
Series C funding round

On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.

April 2018
Magenta Therapeutics raises a $52,000,000 series C round from Access Industries, Be The Match BioTherapies, Casdin Capital, EcoR1 Capital, Eventide Asset Management and Watermill Asset Management.
May 2, 2017
Series B funding round

On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.

May 2017
Magenta Therapeutics raises a $50,000,000 series B round from Access Industries, Atlas Venture, Partners Innovation Fund and Third Rock Ventures.
November 16, 2016
Series A funding round

On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.

November 16, 2016
Magenta Therapeutics raises a $48,500,000 series A round from Third Rock Ventures.
2015
Magenta Therapeutics was founded by Jason Gardner.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
October 4, 2021
FierceBiotech
Five months after former Chief Medical Officer John Davis, M.D., said he'd hit the exit, Magenta Therapeutics has found a replacement in Constellation CMO Jeffrey Humphrey. The new hire comes after Magenta was able to clear a phase 1/2 clinical trial in blood cancer last month following a setback in July.
Kyle LaHucik
July 21, 2021
FierceBiotech
Magenta Therapeutics has been asked by the FDA to pump the brakes on a trial for its blood cancer med before it even got started. The FDA would like the biotech to develop an additional test to inform dose escalation and safety monitoring in the proposed phase 1/2 clinical trial
July 6, 2021
BioSpace
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer - read this article along with other careers information, tips and advice on BioSpace
June 14, 2021
BioSpace
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer - read this article along with other careers information, tips and advice on BioSpace
April 19, 2021
BioSpace
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.